A clinical trial of BCMA-targeted Chimeric Antigen Receptor (CAR) T cell JWCAR129 in patients with relapsed or refractory multiple myeloma
Latest Information Update: 30 Sep 2021
At a glance
- Drugs JWCAR 129 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors JW Therapeutics
- 30 Sep 2021 New trial record
- 27 Sep 2021 According to a JW Therapeutics media release, company has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for this study.